Zacks.com on MSN1 个月
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Following the latest FDA nod, Abrysvo has become the first and only RSV vaccine approved for adults who are younger than 50 ...
Yahoo Finance1 个月
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been ...
Stockhouse1 个月
U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent ...